Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, Yonsei University, Yonsei University Health System, Seoul National University, SNUH SMG-SNU Boramae Medical Center, Seoul National University Bundang Hospital, Chungbuk National University, Chungbuk National University Hospital, Kyungpook National University, Kyungpook National University Chilgok Hospital, Hanmi Pharmaceutical (South Korea), Kyung Hee University
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2947282900